The Stephenson Cancer Center (SCC) at the University of Oklahoma Health Sciences Center (OUHSC) is applying to become a Lead Academic Site in the National Clinical Trials Network (NCTN). The SCC has been a leading accrual site for the NCTN, averaging 205 patients enrolled annually on CTEP trials over the past six years. Leading this effort are SCC Director Robert Mannel, MD (Contact PI) and Associate Director for Clinical Research Scott McMeekin, MD (PI). Both PIs have an outstanding record of scientific and administrative leadership. Along with the grant Investigators, they clearly demonstrate an ability and commitment to function as a coordinated research team and work effectively with components across the NCTN. The SCC is currently a primary institution for Gynecologic Oncology Group (GOG), Radiation Therapy Oncology Group (RTOG), and Alliance (previously CALGB). In addition, it registers patients on ECOG and SWOG trials through the CTSU mechanism and actively participates with ACRIN. The SCC has been a leader for the past decade in the design and conduct of CTEP trials that have defined the standard of care for numerous malignancies. Over the past six years the SCC enrolled 1,232 patients on CTEP therapeutic trials, including an all-time institutional high of 238 patients in 2012 (with projecte enrollment of 258 in 2013), making it a national leader in accrual for the NCTN. As a Lead Academic Site the SCC will continue to work with Network coordinating centers to be a leader in the design and conduct of NCTN trials for newly-developed therapies, including multi-modality treatments, combinations of novel agents, molecularity-based treatments, advanced imaging approaches, quality biospecimen acquisition and translational research. It will accomplish this goal within the context of providing high-quality cancer care and access to NCTN clinical trials for Oklahomans, especially for the state's special populations that experience significantly high rates of cancer health disparities. As the state's only academic cancer center, the SCC plays a crucial role in providing all Oklahomans access to NCTN clinical trials, definitively evaluating novel therapies, raising the standard of care and easing the burden of cancer for the region.

Public Health Relevance

This proposal is directly relevant to public health. As a Lead Academic Site in the NCTN, the SCC will directly contribute to the design and conduct of definitive, randomized, early and late Phase clinical trials for newly-developed therapies, including multi-modality treatments, combinations of novel agents, molecularity- based treatments, and advanced imaging approaches. The ultimate goal is to improve the health of all populations, with an emphasis on special populations such as American Indians

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180798-02
Application #
8841694
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-04-24
Project End
2019-02-28
Budget Start
2015-03-01
Budget End
2016-02-29
Support Year
2
Fiscal Year
2015
Total Cost
$1,221,450
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11
Felix, A S; Brasky, T M; Cohn, D E et al. (2018) Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer 142:1102-1115
Jeske, Yvette W; Ali, Shamshad; Byron, Sara A et al. (2017) FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 145:366-373
Devor, Eric J; Miecznikowski, Jeffrey; Schickling, Brandon M et al. (2017) Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 147:648-653
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Winder, Abigail D; Maniar, Kruti P; Wei, Jian-Jun et al. (2017) Synuclein-? in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer 123:1144-1155
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2017) Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2. Int J Gynecol Cancer 27:730-737
Moore, Kathleen N; Tritchler, David; Kaufman, Kenneth M et al. (2017) Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 147:396-401
Bais, Carlos; Mueller, Barbara; Brady, Mark F et al. (2017) Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. J Natl Cancer Inst 109:

Showing the most recent 10 out of 44 publications